A Minimal PBPK Model for Plasma and Cerebrospinal Fluid Pharmacokinetics of Trastuzumab after Intracerebroventricular Administration in Patients with HER2-Positive Brain Metastatic Localizations

ConclusionContinuous icv infusion of trastuzumab at 1.0  mg/h could be an alternative dosing regimen to rapidly achieve intraventricular CSF therapeutic concentrations.

Source: Pharmaceutical Research - October 11, 2023 Category: Drugs & Pharmacology Source Type: research